18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.
about
Future Directions in Imaging Neurodegeneration.Tau PET imaging: present and future directions.Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses.[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain NetworksImaging and fluid biomarkers in frontotemporal dementia.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Genetics of Frontotemporal Dementia.[18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsyIn vivo retention of 18F-AV-1451 in corticobasal syndrome.18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease.Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's caseFrontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations.Head to head comparison of [(18)F] AV-1451 and [(18)F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia.Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration.New advances in tau imaging in parkinsonism.Flortaucipir tau PET imaging in semantic variant primary progressive aphasia.Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin.Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease.Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.Presymptomatic anterior frontal involvement in corticobasal degeneration.[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review.In vivo 18F-AV-1451 tau-PET signal in MAPT mutation carriers varies by expected tau isoforms.In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.PET imaging of tau protein targets: a methodology perspective.Neuroimaging in Dementia.Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia.18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy.Imaging Protein Misfolding in the Brain Using β-Sheet Ligands[F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansionDisease-related patterns of in vivo pathology in Corticobasal syndrome
P2860
Q31162702-91C45A97-CDA2-477E-9656-77B8E1A27F61Q34680852-08737661-231B-426C-BE68-A0A5C7538C76Q37576743-017BF28A-4BF0-422E-B203-462034FEBCCCQ37577889-EAF58D59-D61B-4C25-8458-CDCAF143843BQ37731919-C9B0F9C9-1082-4E72-B4DB-C80CC7DEA0BFQ38670219-A53C9262-72B6-4B0B-9714-A526EC3A564AQ38979999-E1D00CF9-09E1-4DC1-9AB4-05380365213CQ39017699-0D4E2E69-DD65-4071-A6FD-968E86CF46C5Q41350096-C2109586-D7C7-4440-8954-58FFCD703495Q41591680-D9E68931-56BF-4881-92EA-E8FB86C99DDFQ41600997-9E2A5B83-E30B-4ED0-806A-A0E20137357BQ41695282-AA926D94-325B-4C1B-A31F-CF9AB98E052BQ42334587-0F6B0D87-C137-4FD2-A284-8F399668AC31Q42672461-82B34A4C-FD9E-4AC3-9695-12920B82A00BQ46677826-5DEA2407-538E-4EB5-83F6-7B9A55D09B9DQ46753514-89BE5F5E-B603-40F9-94D9-89998FD7F756Q46936274-87BCCBAC-328B-4AF3-9869-1BE6888168C0Q47329627-A59F41BD-4911-4E53-8EC7-C654B25C884AQ47684719-04E4C3D5-5BE0-4829-B4D1-5A55744ECEC3Q47819962-17F89178-887D-4EBB-9615-2A53545E1CBBQ47886903-04FFB755-4D8E-4E1B-B345-DA0B3CD7326AQ47985518-2A61A683-A09B-4A5A-8002-BCC6343AF4AFQ48389127-9052485D-0A05-4B48-9A30-8EAAF0A20783Q48408108-F0FBA309-C208-4A54-AC1E-2FC5F02A3237Q48505309-63DF55FC-4B60-48C5-A879-F63EE02E1AA2Q48550610-231C988D-641D-4906-8440-D56836A76283Q49295547-EBC479D7-7E22-424C-9417-A00824DB4B59Q49686872-EA5A633F-CC6D-4EDF-BA6A-A7BE9DD1020AQ50026038-60697E19-3690-4479-B68E-F9A6186381B2Q50042841-74EB2F11-ACC3-45C2-9383-C52FA401F657Q51766173-BD3A5459-3965-4C1B-AFE0-285413511A7EQ51800676-3B3AC044-DDA1-4DCE-B7D0-F5F7C200A831Q55254017-8F9269B5-C710-4AED-9CE3-8428CA6C036FQ55318776-59F0B46A-265F-4AFC-A994-D06B2DE7A322Q55359027-CA925B87-6266-4324-943F-EEAAF432C890Q55494083-909094AC-DA40-42EC-898C-D0CFC7B7FFBDQ57168250-A633926F-C16B-4E4F-8A68-30E6269BF48DQ57822208-87CF1262-511E-482B-8755-347C3D67743DQ58794612-B9EB2513-2D00-4DC3-9CA3-9358BC78717E
P2860
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@en
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@nl
type
label
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@en
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@nl
prefLabel
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@en
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@nl
P2860
P50
P356
P1433
P1476
18F-AV-1451 tau PET imaging co ...... ogy in MAPT mutation carriers.
@en
P2093
Michael Honer
Tomas Ohlsson
P2860
P304
P356
10.1093/BRAIN/AWW163
P407
P577
2016-06-29T00:00:00Z